Artelo Biosciences announces presentation of new data on FABP inhibitors

Artelo Biosciences (ARTL) announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 that further validates the therapeutic potential of Fatty Acid Binding Protein, FABP, inhibitors in treating osteoarthritis, OA, pain. Professor Saoirse O’Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: “The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain.” The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain.